Meeting 4 times a year, the primary focus of Council is on the practice of pathology as a profession, including all the professional, clinical and educational functions of the College.
I originally trained as a veterinarian at Liverpool University and practiced small animal medicine for 6 years before moving into laboratory animal medicine at Smith Kline Beecham in 1989.
In 1994 I joined Glaxo Wellcome to retrain as a toxicological pathologist. Since then I have gained 30 years’ experience in regulatory toxicology / safety assessment and discovery support across a range of therapeutic areas (including inhaled medicines, CNS, oncology) and modalities (small molecules and biopharmaceuticals) within large Pharma in the UK and Italy. From 2005 I worked at GlaxoSmithKline, including a number of years as Head of Pathology. In the last 15 years my experience has expanded to include cell and gene therapies for rare diseases, oncology, CNS and auto-immune disease. I was the nonclinical project team member for Strimvelis (for treatment of ADA-SCID) which achieved a successful marketing application in 2016 - the first licensed ex vivo gene therapy anywhere in the world.
After retiring from GSK in March 2021 I have been working as an independent pathology consultant in my own company (Cornelis Consulting Ltd). I have been a Member / Fellow of the RCPath for 25 years and currently chair the Toxicology Specialty Advisory Committee. I am also a former President of the British Society of Toxicological Pathology.
Chair, Trainees Advisory Committee
Clinical Director of Publishing and Engagement, The Royal College of Pathologists
Chair, Research Committee
Chair, Veterinary Pathology SAC